Binding members to PD-L1
US11434294B2 · kind B2 · utility
0Cited by
4References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 24, 2017 |
| Grant date | Sep 6, 2022 |
| Priority date | — |
| Expiry date | Apr 5, 2038 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70532
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to anti-PD-L1 binding members and in particular to monovalent, high potency PD-L1-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of cancer and inflammatory diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.